Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 4 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Monopar Therapeutics changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 10 | 11 | +1 |
| Shares | 198.7K | 231.6K | +32.9K (+16.5%) |
| Value | $471.0K | $322.9K | −$148.1K (−31.4%) |
New holders (3)
Institutions that held Monopar Therapeutics at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Kestra Private Wealth Services, LLC | 23,455 | $32.6K | 0.00% |
| Royal Bank of Canada | 5,000 | $7.00K | 0.00% |
| JPMorgan Chase & Co | 2,414 | $3.00K | 0.00% |
Sold out (2)
Institutions that held Monopar Therapeutics at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Paragon Wealth Strategies, LLC | 58 | $137 |
| Bank of America Corp | 10 | $24 |